11/21 Yahoo! Finance: PFE News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Yahoo! Finance: PFE News - Latest Financial News for PFIZER INC FDA OKs Abilify for autism-linked irritability (AP) November 20, 2009 at 7:27 pm The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb Co. said Friday. Pfizer to pay $6.3 mln to patient in Prempro lawsuit (at Reuters) November 20, 2009 at 7:21 pm [video] Word on the Street (at CNBC) November 20, 2009 at 5:00 pm Taking Fido on Your Trip? There's a Drug for That. (at Motley Fool) November 20, 2009 at 4:38 pm This Baby Is a Nice Addition (at Motley Fool) November 20, 2009 at 4:24 pm J&J stays true to its diversified model (at FT.com) November 20, 2009 at 3:40 pm After a period when break-ups and divestments were in vogue in the pharmaceutical industry, Johnson & Johnson's long-standing healthcare conglomerate model has come back into fashion. Pfizer's Geodon gets expanded FDA approval (AP) November 20, 2009 at 2:15 pm Pfizer Inc. said Friday the Food and Drug Administration approved Geodon as a part of a combination maintenance treatment for bipolar disorder in adults. Pfizer Receives FDA Approval For Geodon® (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults (Business Wire) November 20, 2009 at 1:18 pm NEW YORK----Pfizer today announced that the U.S. Food and Drug Administration has approved Geodon® Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. US healthcare cos set for record lobbying in 2009 (at Reuters) November 20, 2009 at 11:52 am Pfizer's Generics Business Takes Shape (at The Wall Street Journal Online) November 20, 2009 at 11:49 am Pfizer gets FDA approval for intravenous Revatio (AP) November 20, 2009 at 11:16 am Drug developer Pfizer Inc. said Friday the Food and Drug Administration approved an intravenous version of its high blood pressure drug Revatio. 4-Star Stocks Poised to Pop: Merck (at Motley Fool) November 20, 2009 at 9:57 am Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst (Wall Street Transcript) November 20, 2009 at 9:26 am 67 WALL STREET, New York - November 20, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available via The Wall Street Transcript Online. FDA Approves Intravenous Formulation Of Pfizer's Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension (Business Wire) November 20, 2009 at 8:30 am NEW YORK----Pfizer announced today that the U.S. Food and Drug Administration has approved Revatio® Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 inhibitor available in both tablet and intravenous formulations. The Easiest Money You'll Ever Make (at Motley Fool) November 20, 2009 at 7:00 am Trading Review for Vivus Inc. Issued by Beacon Equity (GlobeNewswire) November 20, 2009 at 6:50 am DALLAS -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Vivus Inc. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. Pfizer Is Best Positioned Big Pharma in China - Goldman (at Seeking Alpha) November 20, 2009 at 6:30 am   This email was sent to gatdemit001@gmail.com.  Create Your Account Don't want to receive this feed any longer? Unsubscribe here.